Juglone Effects by Dual Way on mTOR Gene Expression, Which Plays Central Role in Cell Growth, Survival and Metabolism, in PANC-1 and BxPC-3 Pancreatic Cancer Cell Lines
Öz
Background/Aims: Juglone, as a naphthoquinone, has been shown to have cytotoxic and apoptotic effects in various cancer cells and besides this effects it was reported to have anti-invasive and anti-metastatic effects in PANC-1 and BxPC-3 cells in our previous studies. In this study, we investigated the effects of juglone on GRP75, TFAM and mTOR genes encoding key proteins associated with mitochondrial biogenesis and activation in PANC-1 and BxPC-3 pancreatic cancer cells since mitochondria has central roles in cancer cell survival, metastasis and therapeutic resistance.
Methods: In our study; 5, 10, 15 and 20 μM juglone doses were selected as the application doses considering the IC50 value determined after MTT test results and the expressions of the target genes were analyzed by qPCR method after application of juglone doses for 24 hours.
Results: Our study results revealed that juglone had an opposite and strong effects on mTOR expression in both cell lines.
Conclusion: Our findings suggest that juglone has a developable potential and is a promising theurapeutic agent to develop new strategies for the battle with cancer with those effects on mTOR gene which plays a central role in cellular homeostasis and several cellular events including cell growth, survival and metabolism.
Anahtar Kelimeler
Juglone, Pancreatic cancer, Mitochondrial biogenesis, mTOR gene expression
Destekleyen Kurum
Selçuk Üniversitesi
Proje Numarası
21202128
Teşekkür
This study was produced from the MSc thesis of Emine Merve Demirbaş-Büyüktüt and supported by the Selcuk University Scientific Research Projects Coordinatorship (Project no: 21202128)
Kaynakça
- Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer research. 2014;74:2913-21.
- Del Chiaro M, Rangelova E, Halimi A, et al. Pancreatectomy with arterial resection is superior to palliation in patients with borderline resectable or locally advanced pancreatic cancer. HPB : the official journal of the International Hepato Pancreato Biliary Association. 2019;21:219-25.
- Foley K, Kim V, Jaffee E, Zheng L. Current progress in immunotherapy for pancreatic cancer. Cancer letters. 2016;381:244-51.
- Siegel R, Miller KD, Sauer A. Cancer facts & figures 2020. CA Cancer J Clin. 2020;70:7-30.
- Oldfield LE, Connor AA, Gallinger S. Molecular Events in the Natural History of Pancreatic Cancer. Trends in cancer. 2017;3:336-46.
- Sarvepalli D, Rashid MU, Rahman AU, et al. Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer. Critical reviews in oncogenesis. 2019;24:199-212.
- Ahmad T, Suzuki YJ. Juglone in Oxidative Stress and Cell Signaling. Antioxidants (Basel, Switzerland). 2019;8.
- Bhargava UC, Westfall BA. Antitumor activity of Juglans niga (black walnut) extractives. Journal of pharmaceutical sciences. 1968;57:1674-7.
- Cenas N, Prast S, Nivinskas H, Sarlauskas J, Arnér ES. Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells. The Journal of biological chemistry. 2006;281:5593-603.
- Xu H, Yu X, Qu S, Sui D. Juglone, isolated from Juglans mandshurica Maxim, induces apoptosis via down-regulation of AR expression in human prostate cancer LNCaP cells. Bioorganic & medicinal chemistry letters. 2013;23:3631-4.